Eptifibatide

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities:
• hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT.
• In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
• The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed.
• In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
• ACS or PCI:
• 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min.
• ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes.
• ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min.
• ( 2.1 , 2.2 , 2.3 )
• 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily.
• Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters:
• During Medical Management :
• Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h.
• If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h.
• During PCI :
• Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds.
• Heparin infusion after the PCI is discouraged.
• 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first.
• A minimum of 12 hours of infusion is recommended.
• In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery.
• Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.
• Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds.
• Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI.
• Additional boluses during PCI to maintain ACT within target.
• Heparin infusion after the PCI is strongly discouraged.
• Patients requiring thrombolytic therapy should discontinue eptifibatide injection.
• 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit.
• May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil.
• Do not administer eptifibatide injection through the same intravenous line as furosemide.
• May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose.
• With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride.
• Withdraw the bolus dose(s) of eptifibatide injection from the 10-mL vial into a syringe.
• Administer the bolus dose(s) by IV push.
• Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection.
• When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL vial.
• Spike the 100-mL vial with a vented infusion set.
• Center the spike within the circle on the stopper top.
• Discard any unused portion left in the vial.
• Administer eptifibatide injection by volume according to patient weight (see Table 1 ).
• Table 1:
• Eptifiatide Injection Dosing Charts by Weight Patient Weight 180-mcg/kg Bolus Volume 2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2-mg/mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness of eptifibatide in pediatric patients have not been studied.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older).
• There was no apparent difference in efficacy between older and younger patients treated with eptifibatide.
• The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients.
• No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] .

Quoted from the official label, section “Geriatric Use”.

What to discuss with your doctor

Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies.

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS Injection:
• 20 mg of eptifibatide in 10 mL (2 mg/mL), for intravenous bolus.
• Injection:
• 75 mg of eptifibatide in 100 mL (0.75 mg/mL), for intravenous infusion. 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection ( 3 ) 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion (3)

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution in 10-mL vials containing 20 mg of eptifibatide (NDC 52958-402-01) and 100-mL vials containing 75 mg of eptifibatide (NDC 52958-040-01).
• 16.2 Storage Vials should be stored refrigerated at 2-8°C (36-46°F).
• Vials may be transferred to room temperature storage * for a period not to exceed 2 months.
• Upon transfer, vial cartons must be marked by the dispensing pharmacist with a "DISCARD BY" date (2 months from the transfer date or the labeled expiration date, whichever comes first).
• Retain in carton to protect from light until administration. *
• Store at 25 o C (77 o F); excursions permitted to 15-30 o C (59- o F) [see USP Controlled Room Temperature].

Quoted from the official label, section “How Supplied”.

How to store it

• Vials should be stored refrigerated at 2-8°C (36-46°F).
• Vials may be transferred to room temperature storage * for a period not to exceed 2 months.
• Upon transfer, vial cartons must be marked by the dispensing pharmacist with a "DISCARD BY" date (2 months from the transfer date or the labeled expiration date, whichever comes first).
• Retain in carton to protect from light until administration. *
• Store at 25 o C (77 o F); excursions permitted to 15-30 o C (59- o F) [see USP Controlled Room Temperature].

Quoted from the official label, section “Storage and Handling”.

What is in it

• Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue.
• An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties.
• Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide.
• Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation.
• The eptifibatide peptide is produced by solid-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized.
• The structural formula is:
• Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96.
• Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains 0.75 mg/mL of eptifibatide.
• Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. image description

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

15 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Eptifibatide